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Abstract
The cDNA encoding ATP-binding cassette (ABC) multidrug resistance protein MRP1 was originally cloned from a drug-
selected lung cancer cell line resistant to multiple natural product chemotherapeutic agents. MRP1 is the founder of a branch
of the ABC superfamily whose members (from species as diverse as plants and yeast to mammals) share several distinguishing
structural features that may contribute to functional and mechanistic similarities among this subgroup of transport proteins.
In addition to its role in resistance to natural product drugs, MRP1 (and related proteins) functions as a primary active
transporter of structurally diverse organic anions, many of which are formed by the biotransformation of various endo- and
xenobiotics by Phase II conjugating enzymes, such as the glutathione S-transferases. MRP1 is involved in a number of
glutathione-related cellular processes. Glutathione also appears to play a key role in MRP1-mediated drug resistance. This
article reviews the discovery of MRP1 and its relationships with other ABC superfamily members, and summarizes current
knowledge of the structure, transport functions and relevance of this protein to in vitro and clinical multidrug
resistance. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
The development of resistance to multiple drugs
used in cancer chemotherapy is a serious limitation
of this form of treatment. In vitro, broad resistance
to multiple structurally and functionally unrelated
drugs is often observed after intermittent or pro-
longed exposure of tumor cells to only a single agent.
This ‘classical’ multidrug resistance is typically
characterized by cross-resistance to four classes of
commonly used natural product drugs, the anthra-
cyclines, Vinca alkaloids, taxanes and epipo-
dophyllotoxins. It was in such selected multidrug-
resistant cell lines that in 1976, Juliano and Ling
¢rst noted a correlation between decreased drug
accumulation and expression of a 170 kDa cell
surface glycoprotein which they designated P-glyco-
protein [1]. Since this time, the involvement of the
type I P-glycoprotein isoforms in multidrug resis-
tance has been characterized extensively, and gene
transfection studies have demonstrated unequivocally
that these proteins can confer a classical multidrug
resistance phenotype on otherwise drug-sensitive cells
[2,3].
For some time after its discovery, it was widely
believed that P-glycoprotein (encoded by the
MDR1 gene) was the exclusive cause of multidrug
resistance. However, increasing evidence in the mid
to late 1980s suggested that this was not the case.
Several cell lines were isolated that displayed a multi-
drug resistance phenotype in the absence of detect-
able P-glycoprotein expression, despite having under-
gone drug selection by protocols similar to those that
often result in the elevated expression of this protein
[4^8]. One such non-P-glycoprotein multidrug-resis-
tant cell line was H69AR, which was derived from
the parental NCI-H69 (H69) small cell lung cancer
cell line by repeated, transient exposure to doxorubi-
cin [4,5]. H69AR cells displayed moderately high lev-
els of resistance (10^100-fold) to the Vinca alkaloids,
epipodophyllotoxins, doxorubicin, and mitoxan-
trone. In addition, these cells were highly resistant
to daunorubicin, epirubicin, and colchicine [5,8]. Pro-
longed growth of H69AR cells in the absence of drug
resulted in a revertant cell line, H69PR, that had
only 1.5^2.5-fold resistance to most of these drugs
[9]. The multidrug resistance protein, MRP1, was
discovered in 1992 during a di¡erential hybridization
screen aimed at identifying mRNA species whose
levels changed in association with the gain and loss
of the multidrug resistance phenotype in this panel of
lung cancer cell lines [10]. MRP1 mRNA was over-
expressed 100^200-fold in H69AR cells relative to
H69 cells, and was downregulated 20-fold in the re-
vertant H69PR cells relative to H69AR cells. It was
also overexpressed in a doxorubicin-selected multi-
drug-resistant HeLa cell line that did not overexpress
P-glycoprotein. Furthermore, the MRP1 gene, local-
ized to chromosome 16p13.1 by in situ hybridization,
was ampli¢ed in both resistant cell lines [163]. Anal-
ysis of the 1531 amino acid MRP1 sequence identi-
¢ed the protein as a member of the ATP-binding
cassette (ABC) superfamily of transporter proteins,
to which P-glycoprotein also belongs. However, com-
parison of the MRP1 sequence with that of P-glyco-
protein indicated that, although there were limited
regions of similarity, the two proteins were only
15% identical [10,11].
Subsequent to its cloning, it was determined that
MRP1 was probably identical to a 190 kDa protein
(p190) overexpressed in a multidrug-resistant leuke-
mia cell line that was identi¢ed on the basis of its
cross-reactivity with a polyclonal antiserum raised
against a peptide from a highly conserved region of
human P-glycoprotein [12]. Immunoblot and immu-
noprecipitation analyses with MRP1-speci¢c anti-
bodies con¢rmed that MRP1 was a 190 kDa mem-
brane protein [13,14]. Cell fractionation studies and
immunocytochemistry indicated that the protein was
predominantly localized to the plasma membrane in
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drug-resistant cells, with detectable levels present in
intracellular membrane compartments of some cell
types [13^16].
De¢nitive proof that MRP1 is a cause of multi-
drug resistance came from transfection studies. HeLa
cells transfected with MRP1 cDNA that overex-
pressed the MRP1 protein displayed a typical multi-
drug resistance phenotype, accompanied by reduced
drug accumulation, relative to cells transfected with
an ‘empty’ vector [17,18]. Similar ¢ndings were re-
ported by several independent laboratories using dif-
ferent cell types [19^21]. It has also been shown that
MRP1 antisense oligonucleotides can decrease
MRP1 levels and reverse drug resistance in trans-
fected and drug-selected cells [159].
2. The MRP branch of ABC transporter superfamily
The ABC superfamily of transporters, to which
MRP1 and P-glycoprotein belong, is among the larg-
est and most widespread protein superfamilies
known [22] (reviewed elsewhere in this volume). Its
members are responsible for the transport of a wide
variety of substrates, including ions, phospholipids,
steroids, polysaccharides, amino acids and peptides,
across biological membranes. Interest in these pro-
teins has grown enormously in recent years, as super-
family members including the cystic ¢brosis trans-
membrane conductance regulator (CFTR) [23], the
sulfonylurea receptors (SUR1 and SUR2) [24], the
organic anion transporter cMOAT or MRP2 [25],
ABCR [26], and ABC7 [27] have been implicated in
the etiology of various inherited disorders.
ABC transporters contain two types of structural
domains: hydrophobic, polytopic membrane span-
ning domains (MSD), and hydrophilic, cytosolic nu-
cleotide binding domains (NBD). The typical func-
tional ABC transporter has two MSDs and two
NBDs [22], and the majority of identi¢ed eukaryotic
ABC transporters are composed of tandemly arrayed
pairs of subunits (MSD-NBD or NBD-MSD) ex-
pressed as one continuous or two separate polypep-
tides [28]. In most ABC transporters, the binding and
subsequent hydrolysis of ATP by the NBDs is be-
lieved to be coupled to, and provide the energy for,
substrate transport [22]. These domains are highly
conserved, typically showing 30^40% identity among
di¡erent superfamily members in a core region of
about 200 amino acids. The NBDs of ABC super-
family members share two sequence motifs, desig-
nated ‘Walker A’ and ‘Walker B’, with many other
nucleotide binding proteins [29]. Mutational analysis
of a number of ABC proteins indicates that these
two regions are critical for ATPase function [30].
In addition, ABC transporters possess a character-
istic conserved fourteen amino acid ‘active transport
family’ signature (or ‘C’) motif located between the
Walker A and B motifs. In contrast to the NBDs, the
MSDs of ABC transporters are highly divergent.
Current evidence suggests that the majority of these
MSDs possess either four or six membrane-spanning
helices; however, the MSDs of di¡erent family mem-
bers generally show little sequence identity to one
another. This sequence divergence is consistent with
the notion that the MSDs are important determi-
nants of the di¡erent substrate speci¢cities of various
ABC transporters, and in cases where it has been
examined, this appears to be true [31^33].
When the sequence of MRP1 was ¢rst analyzed in
1992, the two most closely related members of the
ABC superfamily were the CFTR chloride channel
(19% identity) and LtPgpA (30% identity) [10]. The
latter is a Leishmania tarentolae protein that was
thought to be a P-glycoprotein homolog [34]. Since
this time, many proteins more closely related to
MRP1 have been identi¢ed in a wide variety of eu-
karyotic organisms, ranging from plants and yeast to
mammals (reviewed elsewhere in this issue). Included
among these are ¢ve human MRP1-related proteins,
designated MRP2, MRP3, MRP4, MRP5, and
MRP6 [35^42].
Phylogenetic analyses indicate that the MRP1-like
transporters belong to a novel branch of the ABC
superfamily (Fig. 1). In general, the MRP1-like pro-
teins possess two features that distinguish them from
other ABC superfamily members [10,43^45]. The ¢rst
feature pertains to the structure of the NH2-proximal
NBD (NBD1). Alignment of the primary sequences
of MRP1, LtPgpA, and CFTR with the human P-
glycoprotein encoded by the MDR1 gene revealed
that, in comparison to P-glycoprotein, these trans-
porters all contain a ‘deletion’ of 13 amino acids
located between the Walker A and B motifs of
NBD1. The corresponding 13 amino acids are
present in the COOH-proximal NBDs of these pro-
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teins and in both NBDs of P-glycoprotein and most
other eukaryotic ABC transporters [10]. This highly
conserved deletion alters the spacing between the
Walker A and B motifs in NBD1 and recent studies
in which the 13 amino acids of NBD1 of human P-
glycoprotein were inserted into NBD1 of MRP1 have
demonstrated that this deletion a¡ects the folding
and activity of this domain [46]. It is present in
most of the MRP1-related proteins, including the
murine mrp1 ortholog and all ¢ve of the more re-
cently identi¢ed human MRPs as well as CFTR (Fig.
2). The absence of these 13 amino acids in CFTR
and in the majority of MRP1-related proteins con-
tributes to the relatively low sequence identity
(V30%) between the two NBDs within each of these
proteins. There is strong evidence that the two NBDs
of CFTR are functionally dissimilar [47,48]. In light
of the shared structural features of the NBDs of
CFTR and the MRP1-like transporters, it appears
likely that the two NBDs of the latter proteins will
also be functionally distinct, and recent analyses of
puri¢ed recombinant MRP1 suggest that this may be
true [49].
A second characteristic feature of MRP1-related
proteins is that they are typically larger than other
full-length ABC proteins. Hydropathy pro¢les of the
MRP1-related proteins can be aligned remarkably
well with those of other eukaryotic ABC transporters
through the four structural domains characteristic of
these proteins [43^45,50]. However, most of the
MRP1-related proteins contain up to approximately
250 additional amino acids at their NH2-termini for
which there is no comparable region in other ABC
transporters, including CFTR. The exceptions are
human MRP4 (which is more related to CFTR)
and human MRP5, both of which appear to lack
the third MSD. The hydropathy pro¢les of the
MRP1-related proteins with a third MSD indicate
that these regions are comprised of an odd number
of transmembrane helices and a predicted extracyto-
solic NH2-terminus. In the case of MRP1 and
MRP2, this has been experimentally veri¢ed (see be-
low) [51,52]. Thus, the MRP1-related proteins typi-
cally have ¢ve domains with a MSD1-MSD2-NBD1-
MSD3-NBD2 con¢guration. The amino acid sequen-
ces of the NH2-terminal MSDs are more variable
than those of the other two MSDs of these trans-
porters. This could be because functional constraints
on this region are low [53]. Alternatively, it is possi-
ble that certain members of the MRP branch of the
superfamily may have arisen by a series of independ-
ent gene fusion events involving a common ancestral
CFTR-like ABC transporter and a number of short-
er polytopic membrane proteins [50,53].
3. Topology studies of MRP1
Newly synthesized MRP1 migrates as a polypep-
Fig. 1. Similarity dendrogram of selected MRP-related ABC
transporters. The dendrogram illustrates the similarity between
the amino acid sequences of selected members of the MRP
branch of the ABC transporter superfamily. Human P-glyco-
protein (hMDR1) was included for comparison. Multiple se-
quence alignment was carried out using CLUSTALX(1.64b).
The protein sequences used (with GenBank accession numbers)
were: human MRP (hMRP1, L05628); human MOAT/MRP2
(U63970); human MRP3 (hMRP3, AB010887); human MRP4
(hMRP4, AF071202); human MRP5 (hMRP5, AB019002); hu-
man MRP6 (hMRP6, AF076622); human CFTR (hCFTR,
P13569); human SUR1 (hSUR1, L78207); Saccharomyces cere-
visiae YCF1 (L35327); Arabidopsis thaliana MRP1 (AtMRP1,
AF008124); Arabidopsis thaliana MRP4 (AtMRP4, AJ002584);
Arabidopsis thaliana MRP2 (AtMRP2, AF020288); Arabidopsis
thaliana MRP3 (AtMRP3, U92650); Leishmania tarentolae P-
glycoprotein (LtPGPA, X17154); human P-glycoprotein
(hMDR1, AF016535).
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tide of approximately 170 kDa in SDS-polyacryl-
amide gels, consistent with the molecular mass of
171 kDa predicted from its cDNA sequence. This
immature form of the protein is rapidly processed
to the larger 190 kDa mature form by the addition
of N-linked glycosylation [15]. When MRP1 was ¢rst
identi¢ed, it was proposed that the protein had eight
and four transmembrane segments in the NH2- and
COOH-proximal halves, respectively [10]. One of the
most important pieces of experimental data that led
to a substantial revision of the originally proposed
topology was obtained by studying post-translational
modi¢cation of the protein by limited proteolysis and
site-directed mutagenesis [43,44,51,54]. These experi-
ments revealed that MRP1 is glycosylated at Asn19
and Asn23 inferring an extracytosolic NH2-terminus,
and at Asn1006 in the COOH-proximal MSD3 [51].
One topological model of MRP1, generated using the
PredictProtein algorithm, is depicted in Fig. 3A [51].
According to this model, MRP1 possesses ¢ve, six,
and four transmembrane segments in MSD1, MSD2,
and MSD3, respectively. This model is consistent
with almost all of the available experimental data.
Thus, it correctly predicts that the NH2-terminus of
the protein is extracytoplasmic and correctly localizes
the glycosylated Asn1006 residue to the extracytoplas-
mic face of the membrane in the loop joining the ¢rst
two transmembrane segments of MSD3. Two of the
potential glycosylation acceptor sites that are not
utilized (Asn354 and Asn1156), are both predicted to
be extracellular. Although this may appear to con£ict
with the PredictProtein model, both of these sites
contain negatively charged amino acids in the +1
position of the glycosylation sequons, and are there-
fore not likely to be e⁄ciently glycosylated [55]. Fur-
thermore, Asn354 is predicted to be situated less than
14 amino acids from the start of a transmembrane
segment, and may therefore not be accessible to the
glycosyltransferase catalytic site [56]. The lack of gly-
cosylation at these two sites is therefore uninforma-
tive with respect to MRP topology of MSD2 and
MSD3. The model also correctly localizes three cy-
toplasmic peptide sequences identi¢ed by epitope
mapping of the MRP1-speci¢c monoclonal antibod-
ies (mAbs) QCRL-1, MRPr1, and MRPm6
[51,57,58].
Fig. 2. Alignments of the amino acid sequences of the ¢rst nucleotide binding domain of human MRP1 with the comparable regions
of other members of the MRP branch of the ABC transporter superfamily. Amino acids 671^790 of MRP1 comprising NBD1 are
shown aligned with the comparable sequences in its murine ortholog mrp1 and other human MRP-related transporters. Multiple se-
quence alignment was performed using CLUSTALX(1.64b). The Walker A, Walker B and ABC signature motifs characteristic of all
ABC proteins are boxed. The protein sequences used (with their GenBank accession numbers) were: human MRP1 (L05628); human
CFTR (P13569); mouse mrp1 (AF022908); human MRP2/MOAT (MRP2, U63970); human MRP3 (AB010887); human MRP4
(AF071202); human MRP5 (AB019002); human MRP6 (AF076622); and human P-glycoprotein (MDR1, AF016535).
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Fig. 3. Proposed membrane topologies of MRP1. Models of the membrane topology of MRP1 are shown with amino acids experi-
mentally determined to be localized to the cytosolic or extracytosolic side of the membrane indicated. Six amino acids have been local-
ized to the extracytoplasmic side of the membrane by N-glycosylation site utilization analysis (N19, N23 and N1006) (¢lled diamonds)
or HA epitope insertion (amino acid positions 4, 574, and 1001) (¢lled triangles). Additional amino acids or regions have been local-
ized to the cytosolic side of the membrane by epitope mapping of MRP1-speci¢c mAbs MRPr1 (amino acids 238^248), QCRL-1 (ami-
no acids 918^924) and MRPm6 (amino acids 1511^1520) (¢lled squares) or by HA epitope insertion (at amino acid positions 163,
271, 653, 938) (open triangles). (A) Topological model of MRP1 generated using the PredictProtein server as described in Hipfner et
al. [51]. Glycosylation sites at Asn354 (N354) and Asn1156 (N1156) that are not utilized but predicted to be extracytosolic are indicated
(open diamonds). (B) Topological model of MSD3 with a more conventional ABC transporter con¢guration of six transmembrane
segments and supported by epitope insertion analysis at amino acid position 1222 [60] (see text for further details).
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The topology of MRP1 has also been examined
using epitope insertion methodology. In these stud-
ies, the membrane orientation of hemagglutinin (HA)
epitope tags inserted at various locations throughout
MRP1 was determined in permeabilized and non-
permeabilized cells expressing the mutant molecules
[59,60]. With the exception of a molecule containing
an HA tag at amino acid position 1222, the immu-
nolocalization of the various HA-tagged MRP1 mol-
ecules tested is consistent with the PredictProtein-
generated model shown in Fig. 3A. The extracyto-
plasmic localization of the HA tag inserted at amino
acid 1222 indicates that MSD3 of MRP1 exists in a
conformation with six transmembrane segments (Fig.
3B) rather than four (Fig. 3A), an arrangement that
is more typical of MSDs of ABC transporters [22].
Interestingly, two HA tags at position 1222 were
required for detectable immunoreactivity and even
with two tags at this site, the reactivity was weak
relative to other HA-tagged molecules. One interpre-
tation of these ¢ndings is that the poor immunoreac-
tivity is attributable to the proximity of the HA tags
to the extracellular face of the plasma membrane.
However, it is also possible that this region of
MRP1 exists in two or more conformational states,
such that the HA tags are accessible from the extra-
cellular surface in only a fraction of the MRP1 mol-
ecules present. The topology of the comparable re-
gion of P-glycoprotein (MSD2) is still a matter of
some debate. Although it is widely accepted that
MSD2 of P-glycoprotein possesses six transmem-
brane segments, there is strong experimental evidence
to suggest that it may also exist in mammalian
cells in a conformation with only four transmem-
brane segments [46,51,61]. By analogy, MSD3 of
MRP1 may also exist in two conformations similar
to those shown in Fig. 3A,B, and could conceivably
shift between the two states as part of its catalytic
cycle [46].
4. Functions of MRP1
4.1. Transport of organic molecules by MRP1
In an interesting example of the convergence of
two seemingly unrelated ¢elds of research, MRP1
has been shown to transport a spectrum of substrates
similar to that attributed to a transporter(s) known
as the multispeci¢c organic anion transporter
(MOAT) [62]. Before its molecular identity was
known, ATP-dependent MOAT-like activity had
been identi¢ed in a number of di¡erent cell types,
including hepatocytes, erythrocytes, mast cells, eosin-
ophils and cardiac cells [63]. MOAT (sometimes re-
ferred to as GS-X pump) activity was considered
responsible for so-called Phase III elimination of
conjugated organic anions produced by Phase I and
Phase II metabolism of many endo- and xenobiotics
[64]. Most of these organic anion substrates are glu-
tathione (GSH), glucuronide, or sulfate conjugated
molecules.
One well characterized MOAT substrate is the cys-
teinyl leukotriene LTC4 [65,66], which is derived
from arachidonic acid in a series of reactions that
culminate in conjugation to GSH. LTC4 is an impor-
tant chemical mediator of in£ammatory responses in
receptor-mediated signal transduction pathways that
control vascular permeability and smooth muscle
contraction. During the puri¢cation of protein(s)
with MOAT-like activity from a LTC4-secreting
mouse mastocytoma cell line, a 190 kDa integral
membrane glycoprotein which could be speci¢cally
photoa⁄nity labelled by LTC4 was identi¢ed
[67,68]. It was subsequently shown that this protein
was MRP1 [69]. Vesicle transport studies with mem-
branes from MRP1-transfected cells con¢rmed that
MRP1 was a primary active transporter of LTC4
with kinetic characteristics similar to those of the
MOAT-like activity in membranes from the masto-
cytoma cell line [69,70]. Further support for the di-
rect transport of LTC4 by MRP1 was provided by
studies with MRP1-speci¢c mAbs. These mAbs,
QCRL-2, QCRL-3 and QCRL-4, recognize non-
overlapping conformation-dependent cytoplasmic
epitopes in MRP1 and are all equally capable of
inhibiting MRP1-mediated LTC4 transport [13,
46,71]. The epitopes recognized by mAbs QCRL-2
and QCRL-3 reside in NBD1 between amino acids
617^658 and 617^932, respectively. In contrast, the
QCRL-4 epitope has been localized to NBD2 (amino
acids 1294^1531) of MRP1 [46]. The precise mecha-
nism by which these mAbs inhibit transport is un-
clear but none of them inhibit azido-ATP labelling of
MRP1. However, mAb QCRL-3 has been shown to
inhibit photolabelling of MRP1 by LTC4, suggesting
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that this mAb may interfere with substrate binding
[71].
Since the initial discovery that MRP1 transports
LTC4, there have been reports of ATP- dependent
uptake of numerous endogenous and exogenous con-
jugated organic anions into inside-out membrane
vesicles isolated from many di¡erent cell types over-
expressing this (or other MRP1-related) protein (re-
viewed elsewhere in this volume) [63,72]. Recent
studies suggest that although MRP1, MRP2 and
MRP3 have many substrates in common, the three
transporters may di¡er in their relative a⁄nities for
individual compounds [38,52,63,73] (reviewed else-
where in this volume). LTC4 remains the highest af-
¢nity substrate known for MRP1, with a Km of ap-
proximately 100 nM. In addition to LTC4, many of
the identi¢ed endogenous MRP1 substrates, such as
bilirubin glucuronides [74], glucuronide and sulfate
conjugated bile salts [75], and glutathione disul¢de
(GSSG) [76,77], are well characterized MOAT sub-
strates. MRP1 also transports the 17L-estradiol 17-
(L-D-glucuronide) [75,78] and the GSH conjugates of
prostaglandin A2 [79], and appears to play a role in
the translocation of certain lipid analogs [80^82].
Among the metabolites of exogenous molecules
transported by MRP1, GSH-conjugated a£atoxin
B1 is the highest a⁄nity substrate identi¢ed to date
[83]. A£atoxin B1 is a mycotoxin produced by certain
Aspergillus species that is bioactivated by a cyto-
chrome P450-mediated Phase I reaction to a muta-
genic and carcinogenic intermediate, a£atoxin B1-8,9-
epoxide [84]. The endo- and exo-epoxides formed are
detoxi¢ed by glutathione S-transferase (GST)-cata-
lyzed conjugation to GSH and, once formed, both
conjugates are actively extruded from the cell [64].
Using a mixture of both stereoisomers, measurement
of a£atoxin B1-SG uptake into inside-out membrane
vesicles from MRP1-transfected HeLa cells yielded
an apparent Km for transport of approximately 200
nM [83]. As observed in studies of MRP1-mediated
LTC4 and 17L-estradiol 17-(L-D-glucuronide) trans-
port, a£atoxin B1-SG transport could be inhibited
by the conformation-dependent MRP1-speci¢c mAb
QCRL-3, con¢rming that a£atoxin B1 is a high af-
¢nity MRP1 substrate [71,78,83]. Identi¢cation of
a£atoxin B1-SG as a substrate was the ¢rst direct
indication that MRP1 may have a role in the elimi-
nation of naturally occurring toxins in addition to its
role in clinical chemotherapy resistance. Interest-
ingly, MRP1 transported the individual endo- and
exo-isomers of a£atoxin B1-SG with similar e⁄ciency
[83]. This indicates that MRP1 may not have rigid
stereospeci¢city requirements of its substrates. In
contrast, other studies suggest that the site of con-
jugation within the parent molecule is probably quite
critical for substrate/inhibitor recognition by MRP1
[78].
Other exogenous molecules that are transported by
MRP1 include the GSH or glucuronide conjugates of
several drugs that are used in cancer chemotherapy.
For example, MRP1 transports synthetic GSH con-
jugates of the alkylating agents melphalan [75] and
chlorambucil [85], as well as VP-16-glucuronide [75]
and doxorubicin-SG [86]. While MRP1 is known to
confer resistance to VP-16 and doxorubicin, it does
not confer resistance to alkylating agents [85,87,88],
and the relevance of in vitro MRP1-mediated trans-
port of such chemically synthesized conjugates of
chemotherapeutic agents to resistance in vivo is not
clear.
4.2. MRP1-mediated drug resistance phenotype
Since its discovery in the highly resistant H69AR
lung cancer cell line, MRP1 has been found to be
overexpressed in multidrug-resistant cell lines derived
from many di¡erent tissue and tumor types, includ-
ing both small cell and large cell lung cancers, car-
cinomas of the colon, breast, bladder, prostate,
thyroid, and cervix, glioma, neuroblastoma, ¢bro-
sarcoma, and various forms of leukemia [89^92].
While most of these cell lines were selected for resis-
tance in doxorubicin, MRP1-mediated resistance is
clearly not restricted to cells selected in this agent,
as other selecting drugs such as epirubicin [93], VP-
16 [94], VM-26 [95], and vincristine [96] have also
given rise to overexpression of MRP1.
In general, the resistance pro¢les of the various
drug-selected, MRP1-overexpressing cell lines are
similar, and typically include moderate to high level
resistance to various natural product drugs. How-
ever, the relative levels of resistance to these drugs
varies from cell line to cell line. While the resistance
phenotype conferred by MRP1 expression may be
in£uenced by the type of cell in which it is expressed,
much of this variability is undoubtedly the result of
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the complexity of cellular responses to drug selection.
Interestingly, overexpression of MRP1 and class I P-
glycoprotein are not mutually exclusive [94,97^100].
It is not clear what factors determine which mecha-
nism(s) of resistance will predominate after selection.
However, analysis of several sets of related cell lines
selected for sequentially higher levels of drug resist-
ance suggest that MRP1 (and possibly topoisomerase
II) may be involved at lower drug concentrations,
whereas P-glycoprotein overexpression often emerges
at higher levels of resistance [94,97,100,101]. On the
other hand, resistant variants of the same parental
cell line exclusively overexpressing either MRP1 (e.g.
H69AR [5,10]) or P-glycoprotein (e.g. H69/LX4
[102]), have been isolated using similar selection pro-
tocols, indicating that this model may be overly sim-
ple.
To circumvent many of the problems associated
with investigating the multifactorial forms of drug
resistance that often emerge in drug-selected cell
lines, the features of MRP1-mediated drug resistance
have been examined extensively in cell lines trans-
fected with MRP1 expression vectors. The resistance
pro¢les of MRP1- and P-glycoprotein-transfected
cells are similar, and typically include moderate levels
of resistance to the anthracyclines, Vinca alkaloids,
and VP-16 [18,20,21,103]. Neither protein confers re-
sistance to platinum-based drugs or to heavy metals
such as Cd2. On the other hand, overexpression of
MRP1 is associated with low level resistance to ar-
senical and antimonial oxyanions [18,104]. The mur-
ine ortholog of MRP1 also confers multidrug resis-
tance and resistance to arsenical and antimonial
oxyanions when expressed in human cells [105].
However, there is a remarkable di¡erence between
the resistance phenotypes conferred by expression
of human MRP1 and mouse mrp1 in the same cell
type. The murine protein does not confer resistance
to the anthracyclines, nor does it transport the or-
ganic anion conjugate 17L-estradiol 17-(L-D-glucuro-
nide) with comparable e⁄ciency [105]. Recent studies
with hybrid murine/human proteins indicate that the
structural causes of these functional di¡erences reside
in the COOH-proximal third of the proteins [106].
As previously observed with P-glycoprotein,
MRP1-mediated resistance is usually associated
with a decreased steady-state cellular accumulation
of drugs. MRP1-transfected cells accumulate less vin-
cristine and daunorubicin than control transfectants
[18,20]. MRP1 overexpression in certain cell lines is
also associated with altered intracellular distribution
of the intrinsically £uorescent drugs doxorubicin or
daunorubicin, often with the accumulation of drug in
cytoplasmic vesicles or a perinuclear, Golgi-like re-
gion [96,107^110]. Interestingly, functional MRP1
has been detected in intracellular vesicles and the
Golgi apparatus of drug-selected GLC4/ADR lung
cancer cells. It has been suggested that, in addition
to e¥ux of drugs across the plasma membrane, intra-
cellular sequestration and vesicular export of drug
may be an important component of MRP1-mediated
resistance in some cell lines [10,110]. However, no
signi¢cant di¡erences in the intracellular distribution
of daunorubicin could be demonstrated in MRP1-
transfected HeLa cells [54]. Furthermore, signi¢cant
levels of intracellular P-glycoprotein and altered sub-
cellular drug distribution have also been observed in
several di¡erent P-glycoprotein overexpressing cell
lines [108,111^114]. Thus, this phenomenon may be
cell type-speci¢c, or may result from secondary adap-
tive changes that occur in both MRP1 and P-glyco-
protein-expressing cells in response to selective pres-
sure from drug exposure.
4.3. Role of GSH in MRP1-mediated drug resistance
and oxidative stress
In vitro transport studies using MRP1-enriched
membrane vesicles under conditions similar to those
used to study drug transport by P-glycoprotein have
failed to demonstrate that MRP1 directly transports
natural product chemotherapeutic agents [71,75,
77,115], and reports to the contrary have been with-
drawn [116,117]. Early clues to the reason why trans-
port of these drugs was not detectable came from
studies using buthionine sulfoximine (BSO). BSO is
a potent irreversible inhibitor of Q-glutamylcysteine
synthase, the enzyme that catalyzes the ¢rst, rate-
limiting step in de novo GSH biosynthesis. Treat-
ment of cells with this agent results in reduction of
intracellular GSH levels by as much as 90% within
24 h, depending on the cell line examined. Several
studies showed that BSO treatment could enhance
drug accumulation and toxicity in MRP1-overex-
pressing cell lines, although the extent of chemosen-
sitization varies to some degree with respect to the
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individual cell line and drug being tested [54,118^
122]. In some cases (but not in others), BSO had
similar e¡ects on drug-sensitive parental or P-glyco-
protein-overexpressing cell lines [54,118^120,123,
124]. Several lines of evidence suggest that modula-
tion of MRP1 activity by BSO is the direct result of
GSH depletion. First, acute exposure of cells to BSO
had no e¡ect on drug accumulation, suggesting that
BSO itself does not inhibit MRP1-mediated trans-
port [119]. In addition, treatment with the mem-
brane-permeable GSH ethyl ester increased cytoplas-
mic GSH levels and concomitantly decreased
daunorubicin accumulation in two BSO-treated,
MRP1-overexpressing cell lines [120]. Although the
e¡ects of BSO do not appear to be entirely MRP1-
speci¢c, these observations taken together provided
strong evidence that the involvement of GSH is an
important feature of MRP1-mediated resistance
[125].
Given that MRP1 apparently does not directly
transport unmodi¢ed natural product chemothera-
peutic drugs but can transport anionic Phase II bio-
transformation products conjugated to GSH or other
small molecules in vitro, it was speculated that
MRP1 confers resistance by eliminating drug conju-
gates from cells [125]. In support of this idea, trans-
fection studies demonstrated that GSTs and MRP1
may act synergistically to confer resistance to certain
drugs. For example, co-expression of a Z class GST
and MRP1 in MCF7-derived breast cancer cells re-
sulted in moderately high levels of resistance to 4-
nitroquinoline 1-oxide as well as cellular e¥ux of a
GSH-conjugated metabolite of this drug, whereas ex-
pression of either protein alone did not [126]. Sim-
ilarly, both MRP1 and GSTK overexpression were
required for resistance to the alkylating agent chlor-
ambucil in the same system [88]. Although it seems
unlikely that increased elimination of drug metabo-
lites (which are typically less toxic) by MRP1 would
have major chemoprotective e¡ects, e⁄cient elimina-
tion of these biotransformation products may pre-
vent end-product inhibition of the Phase II enzymes
required for xenobiotic conjugation.
There are, however, a number of problems with
this model of MRP1-mediated drug resistance. For
example, although the GST/MRP1 co-expression
studies cited above suggest that increased formation
and elimination of drug conjugates should result in
resistance to 4-nitroquinoline 1-oxide and chloram-
bucil, neither of these drugs is known to be part of
the MRP1 resistance phenotype. Furthermore, cells
co-expressing MRP1 with GSTs of the K, W or Z
classes showed no increased resistance to the natural
product oncolytics vincristine, doxorubicin, and VP-
16, relative to cells expressing MRP1 alone [88].
These observations are not surprising in light of the
fact that conjugation to GSH is not known to be a
major pathway for metabolism of most of the drugs
to which MRP1 confers resistance. In addition, there
is no convincing evidence that drug-resistant tumor
cell lines carry out Phase II conjugation reactions to
any signi¢cant extent [123,127]. These reactions oc-
cur primarily in the liver, and it is highly improbable
that cells of all of the tissue origins in which MRP1
overexpression has been shown to confer drug resist-
ance would be capable of forming Phase II conju-
gates at levels su⁄cient for resistance. Consistent
with the view that MRP1-mediated resistance to nat-
ural product drugs is not dependent upon Phase II
biotransformation, only unconjugated forms of vin-
cristine and daunorubicin were found in the culture
medium of MRP1-transfected drug-resistant cells ex-
posed to these drugs [123].
4.4. Transport of unmodi¢ed drugs and GSH
The inability of MRP1 to directly transport natu-
ral product chemotherapeutic agents is in agreement
with the observation that these xenobiotics are poor
inhibitors of MRP1-mediated transport of other sub-
strates. Even at extremely high drug concentrations
(100 WM), little inhibition of LTC4 transport was
observed with doxorubicin, daunorubicin, vincris-
tine, vinblastine, VP-16, or paclitaxel [70,71]. How-
ever, the inhibitory potency of some of these drugs
was markedly increased in the presence of reduced
GSH with the most dramatic enhancement observed
with the Vinca alkaloids, vincristine and vinblastine
[71]. It was subsequently demonstrated that uptake
of unmodi¢ed vincristine into plasma membrane
vesicles from MRP1-transfected HeLa cells was
both ATP- and GSH-dependent and could be inhib-
ited by the MRP1-speci¢c mAb QCRL-3 [71,115].
Vincristine uptake in the absence of reduced GSH
was extremely low and showed no ATP dependence,
whereas active vincristine transport increased with
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increasing concentrations of GSH in a physiologi-
cally relevant concentration range (up to 5 mM)
[71,115]. These results have since been con¢rmed in
other cell types [85,128]. Similarly, GSH stimulated
the active transport of unmodi¢ed a£atoxin B1 by
MRP1 [83]. This transport was not the result of up-
take of a spontaneously formed GSH conjugate of
a£atoxin B1 because evidence of a£atoxin B1 metab-
olites other than the unmodi¢ed parent compound
could not be found [83]. ATP- and GSH-dependent
uptake of unmodi¢ed daunorubicin into membrane
vesicles from MRP1-overexpressing cells has also
been demonstrated and again, is inhibitable by
mAb QCRL-3 [128].
The ¢nding that MRP1-mediated vincristine, a£a-
toxin B1, and daunorubicin transport could be stimu-
lated by GSH suggests that either MRP1 co-trans-
ports these compounds with GSH or that GSH in
some way activates MRP1, facilitating substrate
binding and/or transport. Exposure of wild-type
(mrp1=) embryonic stem cells or resistant MRP1-
overexpressing tumor cells to sodium arsenite or VP-
16 stimulated GSH e¥ux to a greater extent than in
mrp13=3 stem cells or drug-sensitive tumor cells
[123,129]. However, GSH itself appears not to be a
substrate of MRP1 [71,75,130]. Strong support for a
co-transport mechanism was provided by studies ex-
amining the transport of both vincristine and GSH
in vitro [115]. Thus, ATP-dependent uptake of
[3H]GSH into membrane vesicles from MRP1-trans-
fected cells was stimulated by vincristine in a dose-
dependent manner. Furthermore, as for other MRP1
substrates, this VCR-stimulated active transport of
GSH could be inhibited by mAb QCRL-3 (and other
conformation-dependent MRP1-speci¢c mAbs) [115].
The mechanism of MRP1-mediated resistance to
other chemotherapeutic agents remains unclear. For
example, although vinblastine and VP-16 are both
able to enhance GSH transport [115], GSH-stimu-
lated transport of these drugs has not yet been dem-
onstrated. Conversely, daunorubicin is transported
by MRP1 in a GSH-dependent manner [128], yet
neither daunorubicin nor doxorubicin stimulated
GSH transport in MRP1-enriched membrane vesicles
or GSH e¥ux from intact cells [115,120,123]. It is
possible that these apparent discrepancies are the re-
sult of technical limitations of the transport assays.
For example, the levels of GSH-stimulated unmodi-
¢ed vincristine transport are modest compared with
many conjugated substrates, so the levels of GSH-
dependent transport of some drugs may be below
reliable detection limits. In order to measure GSH-
stimulated daunorubicin uptake into membrane
vesicles, for instance, it was ¢rst necessary to inhibit
non-MRP1-mediated, ATP-dependent uptake with
the vacuolar H-ATPase inhibitor ba¢lomycin A1
to prevent proton gradient formation [128]. It also
remains possible that the discrepancies may re£ect
real mechanistic di¡erences in the way in which
MRP1 confers resistance to di¡erent drugs. Resolu-
tion of this issue requires further investigation.
Because of its involvement in GSH-related cellular
processes, MRP1 is a potentially important determi-
nant of a cell’s ability to tolerate oxidative stress.
Expression of MRP1 protects cells directly against
certain agents capable of generating reactive oxygen
species (e.g. anthracyclines) by reducing cellular ac-
cumulation of the parent compound. MRP1 is also
capable of transporting GSH conjugates formed in
the defense against oxidative stress. In addition to
Phase II biotransformation products, MRP1 can
transport GSSG, a product of antioxidant action
[76,77]. Under conditions of oxidative stress, when
the rate of GSH oxidation exceeds the rate of
GSSG reduction by GSH reductase, this activity of
MRP1 may be important to prevent excess GSSG
from reacting with protein thiol groups. Further-
more, it has been pointed out that two of the most
harmful e¡ects of reactive oxygen species, lipid per-
oxidation and oxidative DNA damage, result in the
production of 4-hydroxyalkenals and base propenols.
These compounds are established substrates for
mammalian GSTs [131], and their Phase II metabo-
lites are transported by mammalian GSH conjugate
transporters [132], suggesting that they are likely sub-
strates for MRP1 [70,133]. Thus, MRP1 is well suited
for helping cells cope with the causes and consequen-
ces of oxidative stress.
Nevertheless, evidence for the general involvement
of MRP1 in an oxidative stress response has been
equivocal. Some studies have suggested that the ex-
pression of MRP1 may be co-ordinately upregulated
in certain cell lines with that of the Q-glutamylcys-
teine synthetase heavy chain gene in response to
chemicals known to cause oxidative stress [134,135].
For example, MRP1 protein levels, intracellular
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GSH levels, and LTC4 transport activity were all
increased by treatment with 1-(4-amino-2-methyl-
5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea
in one human glioma cell line [135]. However, the
e¡ects were rather small and a similar upregulation
of MRP1 and Q-glutamylcysteine synthetase expres-
sion was not observed in several additional cell lines
in response to various oxidative stresses (E.U. Kurz,
K. Sparks, R.G. Deeley, S.P.C. Cole, unpublished
observation), indicating that this may represent a
cell type-speci¢c e¡ect.
4.5. Structure-function analyses of MRP1
In light of the structural and mechanistic di¡eren-
ces between the MRP-related ABC transporters and
other members of this superfamily, there has been
considerable interest in structure-function analyses
of MRP1. One approach that has proven to be quite
informative has been to express intact MRP1 and its
constituent domains in a baculovirus system.
Although underglycosylated, full-length MRP1 is ex-
pressed at high levels in insect cells and has kinetic
parameters for LTC4 transport and competitive in-
hibition pro¢les that are similar to the protein ex-
pressed in mammalian cells [136,137]. MRP1 ’half-
molecules’ composed of amino acids 1^932 or 932^
1531 (i.e. separated in the poorly conserved linker
region) had no transport activity when expressed in-
dependently. However, when co-expressed, the two
halves formed a fully functional LTC4 transporter,
demonstrating that they do not need to be covalently
attached to associate properly [136]. MRP1 half-mol-
ecules that are lacking most of the linker region (ami-
no acids 1^858 and 932^1531) can also associate to
form a functional transporter, indicating that this
region is dispensable for LTC4 transport activity
[138].
An area of particular focus has been elucidation of
the role of the unique NH2-terminal MSD in the
function of MRP1 since initial studies suggested
that this region was essential for transport [138].
Thus, truncated MRP1 molecules containing amino
acids 229^1531 or 281^1531 expressed in insect cells
were inactive but LTC4 transport activity could be
reconstituted when either polypeptide was co-ex-
pressed with a fragment containing amino acids 1^
281. On the other hand, co-expression of amino acids
1^227 and 281^1531 did not result in detectable
transport activity, suggesting that at least a portion
of the cytoplasmic region joining MSD1 and MSD2
was critical for activity [138]. In a separate study, it
was reported that an NH2-terminally truncated
MRP1 molecule containing amino acids 204^1531
(which is lacking just the ¢ve transmembrane seg-
ments of MSD1) transported LTC4 only slightly
less e⁄ciently than the intact protein when expressed
in both mammalian and insect cells [137]. Taken to-
gether, these results suggest that determinants lo-
cated between amino acids 204 and 229 in the third
intracellular loop connecting MSD1 to MSD2, rather
than the entire MSD1 region itself, are essential for
transport. Unlike most of MSD1, this region con-
tains a peptide segment that is relatively highly con-
served among MRP1-like proteins [45,50,137] and
may therefore be important for the transport activity
of all proteins in this branch of the ABC superfam-
ily. Interestingly, MRP1 lacking its extracytosolic
NH2-terminus and ¢rst transmembrane K-helix (ami-
no acids 1^66) was inactive for reasons which are
presently unclear [138]. On the other hand, MRP1
lacking its NH2-terminal 203 amino acids properly
localized to the basolateral membranes of polarized
MDCKII cells, suggesting that MSD1 is also not
essential for tra⁄cking [137].
4.6. ATPase activity of MRP1
As demonstrated for P-glycoprotein and many
other ABC superfamily transporters, it was presumed
that ATP hydrolysis in the NBDs provides the en-
ergy required for transport by MRP1, because the
protein can be labelled with azido-ATP, and
MRP1-mediated transport is not supported by non-
hydrolyzable ATP analogs [68,70,71,139]. Low level
stimulation of ATPase activity by the GSH conju-
gated substrate dinitrophenyl-SG was reported in
membrane vesicles isolated from MRP1-overexpress-
ing lung cancer cells suggesting that MRP1 possesses
substrate stimulatable ATPase activity [140]. MRP1
ATPase activity has been more extensively character-
ized with puri¢ed recombinant and native protein.
Histidine-tagged recombinant MRP1 puri¢ed from
transfected cells had a relatively high basal ATPase
activity comparable to that of P-glycoprotein when
assayed in bu¡er containing lipids in the absence of
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detergents. This activity could be stimulated up to
two-fold by the addition of known MRP1 substrates
such as LTC4 and GSSG. Somewhat surprisingly,
ATPase activity was also stimulated by several anti-
cancer drugs, including Vinca alkaloids and anthra-
cyclines, that have not been shown to be directly
transported by MRP1 in the absence of GSH [21].
The Km of MRP1 for ATP measured in this study (3
mM), although similar to that of puri¢ed P-glyco-
protein, is more than an order of magnitude higher
than values determined in vesicle transport assays
[69,71,77,78], an observation that remains unex-
plained. Native MRP1 isolated from multidrug-re-
sistant H69AR cells using a mAb QCRL-1 a⁄nity
resin and then reconstituted into phospholipid
vesicles also showed basal ATPase activity but
much lower than that of the histidine-tagged
MRP1. However, MRP1 puri¢ed from H69AR cells
exhibited properties more consistent with those de-
termined in membrane transport assays. Thus, the
reconstituted MRP1 ATPase activity was not stimu-
lated by anticancer drugs but was stimulated by the
organic anion substrates LTC4, 17L-estradiol 17-(L-
D-glucuronide), and GSSG, over a concentration
range consistent with their known Km values. Fur-
thermore, reconstituted MRP1 had a Km value for
ATP (100 WM) comparable to that measured in
transport assays [166]. The reasons for discrepancies
between the properties of soluble recombinant histi-
dine-tagged MRP1 and reconstituted native MRP1
are not known, but may well be related to the in£u-
ence of the lipid environment on activity. Consistent
with the notion of substrate-stimulatable ATP hy-
drolysis, a number of MRP1 substrates have been
shown to increase vanadate-induced trapping of a
photoactivatable ATP analog by the protein [141].
5. MRP1 and clinical multidrug resistance
There is considerable interest in determining the
potential involvement of MRP1 in clinical multidrug
resistance and a number of di¡erent MRP1-speci¢c
mAbs, including mAbs QCRL-1, QCRL-3, MRPr1,
and MRPm6, have been used in a wide variety of
immunoassays for the analysis of MRP1 expression
and localization in both normal and malignant tis-
sues [13,14]. The use of these reagents has been fa-
cilitated by epitope mapping studies demonstrating
that all of these mAbs bind to distinct regions of
the protein [46,57,58]. The linear epitopes bound by
mAbs QCRL-1, MRPr1, and MRPm6 have been
mapped to a resolution of 10 amino acids or less,
and have been shown to reside in the protease-sensi-
tive cytoplasmic loops connecting MSD1 to MSD2
(MRPr1) and NBD1 to MSD3 (QCRL-1), or near
the COOH-terminus of the protein (MRPm6) [57,58].
Alignment of the linear epitope sequences of mAbs
Table 1
Epitope sequences of MRP1-speci¢c monoclonal antibodies
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QCRL-1, MRPr1 and MRPm6 with the comparable
regions in other MRP1-like proteins suggests that
these mAbs are very unlikely to cross-react with
the other human MRP1-related proteins (Table 1).
The expression of MRP1 protein and/or mRNA
has been detected in almost every tumor type exam-
ined, including both solid tumors (lung, gastrointes-
tinal and urothelial carcinomas, neuroblastoma, glio-
ma, retinoblastoma, melanoma, cancers of the
breast, endometrium, ovary, prostate, and thyroid)
[89,142^154] and hematological malignancies
[89,142,155^158]. Among the common tumor types,
expression of high levels of MRP1 is particularly
frequent in the major histologic forms of non-small
cell lung cancer. These studies suggest that MRP1
may be involved in resistance of some tumor types
or subgroups of patients, although no comprehensive
picture of the general relevance of this protein to
clinical resistance has yet emerged. The di⁄culty of
clearly establishing a causative role for MRP1 (and
other resistance-associated proteins, including P-gly-
coprotein) in clinical multidrug resistance can be at-
tributed to a number of di¡erent factors. For exam-
ple, the broad spectrum of drugs encompassed by
clinical drug resistance indicates that multiple resis-
tance mechanisms are likely involved. In addition,
di¡erences in the methods used to quantify MRP1
in clinical samples have almost certainly contributed
to the sometimes discrepant results reported by dif-
ferent investigators. The design and execution of
more informative studies to address the role of re-
sistance proteins in chemotherapy failure has been
hindered by di⁄culties in obtaining suitable patient
samples (e.g. pre- and post-chemotherapy samples
from the same patient) for practical and/or ethical
reasons.
Despite these and other problems, several studies
have found expression levels of MRP1 to be of prog-
nostic signi¢cance. Ampli¢cation of the N-myc onco-
gene has been established to be a powerful indicator
of poor response to chemotherapy and poor outcome
in childhood neuroblastoma [159]. Analyses of neu-
roblastoma tumor specimens from 85 patients re-
vealed levels of MRP1 mRNA that were signi¢cantly
higher in tumors with N-myc ampli¢cation. Further-
more, MRP1 mRNA levels were a strong predictor
of reduced survival independent of N-myc ampli¢ca-
tion. These results suggest that MRP1 expression
may account in part for the association between N-
myc ampli¢cation and reduced survival [160,161].
One particular subtype of acute myeloid leukemia,
designated M4Eo, is associated with an inversion in
chromosome 16, inv(16)(p13q22) [162]. The MRP1
gene maps proximal to the short arm breakpoint
this inversion [10,163] and in one study of a subset
of 22 M4Eo patients, one MRP1 allele was found to
be disrupted by this inversion. Patients in this subset
had a signi¢cantly increased time to death or relapse
after diagnosis compared to patients in which both
MRP1 alleles were retained, suggesting that hemi-
zygosity for MRP1 rendered the leukemic cells of
these patients more sensitive to chemotherapy [164].
MRP1 has also been associated with the rare chemo-
therapy failure in cases of retinoblastoma which were
treated with anticancer drugs and the P-glycoprotein
inhibitor, cyclosporin A, suggesting that MRP1-
mediated resistance may emerge in cases where P-
glycoprotein overexpression is prevented by the use
of P-glycoprotein chemosensitizers [150]. However,
both the M4Eo leukemia and retinoblastoma studies
were based on very small numbers of patient sam-
ples, and further analysis will be required before any
¢rm conclusions can be drawn about the involvement
of MRP1 in drug sensitivity or resistance of these
malignancies.
6. Conclusions
Since the discovery of MRP1 in 1992, there has
been considerable progress in our understanding of
the biology of this protein. Many of the features of
multidrug resistance associated with overexpression
of MRP1 have been well characterized, and have
been shown to be very similar to, but clearly distinct
from, those of P-glycoprotein-mediated drug resist-
ance. One notable aspect of MRP1-mediated resist-
ance, related to the role of this protein as a broad
speci¢city transporter of conjugated organic anions,
is the involvement of GSH. Current evidence sug-
gests that MRP1 co-transports some natural prod-
ucts drugs with GSH, but this appears not to be
true for all drugs to which this protein confers resist-
ance [165]. MRP1 was the founding member of a
subfamily of ABC transporters characterized in
part by the presence of a unique NH2-terminal
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MSD. Structure-function analyses have begun to ad-
dress the importance of this and other domains of
the protein for its expression and activity. Further
characterization of the mechanism by which MRP1
transports its substrates will be facilitated by recent
developments, including improved structural models
of the protein supported by biochemical and immu-
nological evidence and the puri¢cation and reconsti-
tution of the protein in an active, transport compe-
tent form.
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